The Commission adopted two delegated regulations on 20 March 2026 that quietly reshape key compliance obligations for medical device manufacturers. This article covers the first and, for many companies, the more impactful of the two: C(2026) 1798, which expands the list of implantable and Class III devices that are exempt from the obligation to perform clinical investigations.
The second regulation, C(2026) 1809, addresses a separate but related exemption for Class IIb implantable devices in the context of technical documentation assessment. We cover that in a separate article.
Neither regulation has yet been published in the Official Journal of the European Union. Both will enter into force 20 days after OJEU publication.
What Article 61(6)(b) Does
Under Article 61 of the MDR, manufacturers of implantable devices and Class III devices are generally required to perform a clinical investigation as part of generating the clinical data needed to support their clinical evaluation. Clinical investigations are resource-intensive, time-consuming, and expensive. For many manufacturers, they represent one of the most significant cost and time burdens in the MDR compliance pathway.
Article 61(6)(b) provides an exception. Where a device type is listed as a Well-Established Technology (WET) and the clinical evaluation is based on sufficient clinical data and complies with any relevant product-specific Common Specifications, the manufacturer is exempt from the obligation to conduct a clinical investigation.
The WET criteria, set out in MDCG 2020-6, require a device to have:
- A common, simple and stable design with little evolution
- A well-known safety profile with no history of significant safety issues
- Well-known clinical performance characteristics that are standard of care
- A long history on the EU market
Article 61(8) empowers the Commission to expand this list by delegated act. That is exactly what C(2026) 1798 does.
What C(2026) 1798 Changes
The regulation replaces the existing Article 61(6)(b) list in its entirety with a new, expanded version. The updated list is grouped into two categories.
The first category (a) retains the original devices that were already in the MDR at publication: sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors.
The second, newly expanded category (b) adds a substantial number of device types. The full list now includes:
cranial perforators, cranio-blades, catheter passers, patties and strips, magnets for implantable pulse generators, port plugs, stylets and stylet guides, needles, needle holders, forceps, cannulas, atrioseptostomy balloon catheters, catheters coated with anticoagulants, blood bags incorporating anticoagulants, port catheters, introducers, dilators, ventricular drains, feeding tubes, suture pledgets, suture sleeves, suture buttons, gastrostomy buttons, bone tacks, bone wax, bone fillers, bone substitutes, stem centralisers, diaphyseal obturators, radiography markers, fiber ligatures, tubal extraluminal ligation devices, transpalatal distractors, nails, anchors, spinal posterior fixations, textile braids, dental implants, orthodontic devices, dental barriers, dental veneers, suspensory fixations and cinches, reusable surgical instruments, springs for skull enlargement, guidewires, pressure wires, pacing wires and leads, snares, lead caps, fixation and connector tools, endovascular embolisation coils, embolisation particles, cables, shunts and internal defibrillation paddles.
This is a materially longer list than what existed before, covering a wide range of implantable and Class III device types across cardiovascular, orthopaedic, dental, neurosurgical and general surgery categories.
What This Means in Practice
For manufacturers whose device type now appears on the list, the exemption removes the obligation to conduct a clinical investigation as part of MDR compliance. That is a significant relief in terms of both cost and timeline.
However, there are two important nuances to keep in mind.
The clinical evaluation obligation remains. Recital (5) of the regulation is explicit on this point: manufacturers are still required to plan, conduct and document a clinical evaluation in accordance with Article 61 MDR. The WET exemption removes the need for a clinical investigation but it does not remove the need for a robust clinical evaluation. Manufacturers of WET devices will still need to generate and appraise clinical data from existing sources, literature and post-market surveillance. The standard of clinical evidence required is not reduced; only the route to generating it changes.
Compliance with any applicable Common Specifications is still required. The exemption applies only where the clinical evaluation is based on sufficient clinical data and is in compliance with relevant product-specific Common Specifications, where such a CS exists. Manufacturers should check whether a CS applies to their device type before assuming the exemption is straightforwardly available.
An Important Question: What Counts as “Similar”?
Article 61(8) MDR, the legal basis for this regulation, empowers the Commission not only to expand the WET list but also to treat devices “similar” to those listed as falling within the exemption. The regulation itself lists device types at a category level rather than individual product descriptions.
This creates a genuine interpretive question. Manufacturers whose device is not explicitly named but shares the design characteristics, safety profile and market history of a listed type will need to make a careful, documented assessment of whether their device falls within a listed category. This assessment should be part of the clinical evaluation and technical documentation, with clear reasoning on the similarity determination.
If in doubt, this is a conversation worth having with your notified body before relying on the exemption.
Timing
Both delegated regulations were adopted on 20 March 2026. They have not yet been published in the OJEU. The entry into force date is 20 days after OJEU publication. Until that date, the existing Article 61(6)(b) list remains in effect.
Manufacturers should plan ahead now, but should not formally rely on the expanded list until OJEU publication has occurred.
What to Do Next
If you manufacture implantable or Class III devices, the first step is to check the full enumerated list in C(2026) 1798 and assess whether your device type qualifies. This involves both a classification assessment (is your device implantable or Class III?) and a WET criteria assessment (does it meet the four criteria in MDCG 2020-6?).
If your device qualifies, review your clinical evaluation strategy. Depending on where you are in your MDR compliance cycle, this could affect your planned clinical investigation programme, your clinical evaluation timeline, and the resources you have allocated to clinical data generation.
If you are mid-process and already have a clinical investigation planned, do not cancel it unilaterally. Discuss the implications with your notified body first.
Not sure whether your device is on the list or what this means for your clinical evaluation approach? We can help you work through it. Get in touch for a straightforward conversation.